Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05216432
Title First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Relay Therapeutics, Inc.

head and neck squamous cell carcinoma

Her2-receptor negative breast cancer

ovarian clear cell carcinoma

cervical cancer

Advanced Solid Tumor



Fulvestrant + RLY-2608

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
HealthONE Recruiting Denver Colorado 80218 United States Details
Florida Cancer Specialists Recruiting Orlando Florida 32827 United States Details
Massachusetts General Hospital Recruiting Boston Massachusetts 02114 United States Details
Columbia University Herbert Irving Comprehensive Cancer Center Recruiting New York New York 10032 United States Details
Memorial Sloan Kettering Recruiting New York New York 10065 United States Details
Tennessee Oncology Recruiting Nashville Tennessee 37203 United States Details
The University of Texas M.D. Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
NEXT Virginia Recruiting Fairfax Virginia 22301 United States Details
*Shaded cells indicate that there was no data available from for the field